Public Employees Retirement System of Ohio Takes $1.55 Million Position in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Public Employees Retirement System of Ohio acquired 32,881 shares of Prestige Consumer Healthcare, valued at approximately $1.55 million, giving it a 0.07% stake. Institutional investors collectively own 99.95% of the company.
• Analyst sentiment is mixed: PBH has an average rating of Hold and an average price target of $70.75, while recent actions included downgrades from Oppenheimer and Weiss Ratings and a lower Canaccord Genuity price target.
• Prestige Consumer Healthcare recently exceeded quarterly expectations, reporting $0.98 EPS versus the $0.89 consensus and $265.71 million in revenue, up 6.5% year over year. Shares opened at $52.17, near the lower portion of their 12-month range.

Public Employees Retirement System of Ohio acquired a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 32,881 shares of the company's stock, valued at approximately $1,554,000. Public Employees Retirement System of Ohio owned 0.07% of Prestige Consumer Healthcare at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. raised its stake in Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company's stock worth $26,000 after acquiring an additional 219 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after purchasing an additional 269 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock worth $35,000 after purchasing an additional 236 shares during the period. Danske Bank A S bought a new position in shares of Prestige Consumer Healthcare in the third quarter worth approximately $37,000. Finally, Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter worth $30,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on PBH. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 14th. Zacks Research raised shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a report on Monday, August 10th. Weiss Ratings lowered Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, June 25th. Finally, Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of "Hold" and an average price target of $70.75.

Prestige Consumer Healthcare Stock Down 0.2%

NYSE PBH opened at $52.17 on Tuesday. Prestige Consumer Healthcare Inc. has a 12 month low of $42.62 and a 12 month high of $71.07. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. The stock has a market cap of $2.47 billion, a PE ratio of 14.61, a P/E/G ratio of 1.64 and a beta of 0.33. The stock's 50 day moving average is $50.84 and its 200 day moving average is $53.95.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. The business had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company's revenue was up 6.5% on a year-over-year basis. During the same period last year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.